Quick Answer
Serina Therapeutics, Inc. reported Net Income Loss of -$19.18 million for the year ending 2025.
- Serina Therapeutics, Inc. showed a decrease of -72.2% in Net Income Loss from 2024 to 2025.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$235.0 thousand | Q2 2018: -$1.93 million | Q3 2018: -$2.15 million | Q1 2019: -$3.13 million | Q2 2019: -$3.09 million | Q3 2019: -$3.22 million | Q1 2020: -$3.19 million | Q2 2020: $2.00 million | Q2 2020: -$2.69 million | Q3 2020: -$2.54 million | Q1 2021: -$2.09 million | Q2 2021: -$2.47 million | Q3 2021: -$1.96 million | Q1 2022: -$2.71 million | Q2 2022: -$2.62 million | Q3 2022: -$2.44 million | Q1 2023: $1.66 million | Q2 2023: $808.0 thousand | Q3 2023: $1.75 million | Q1 2024: -$15.02 million | Q2 2024: $5.20 million | Q3 2024: $1.41 million | Q1 2025: -$4.81 million | Q2 2025: -$6.45 million | Q3 2025: -$4.59 million.
- Over the full 10 years of available data (2017 to 2025), Serina Therapeutics, Inc.'s Net Income Loss has declined by 191.5%.
- Historical annual values: Fiscal year 2025: -$19.18 million | Fiscal year 2024: -$11.14 million | Fiscal year 2023: $5.27 million | Fiscal year 2022: -$10.46 million | Fiscal year 2021: -$8.68 million | Fiscal year 2020: -$10.87 million | Fiscal year 2020: $2.00 million | Fiscal year 2019: -$12.15 million | Fiscal year 2018: -$7.50 million | Fiscal year 2017: -$6.58 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: